Answers are grounded in this paper and cite their sources.
Sorafenib is the first drug of proved clinical efficacy on hepatocellular carcinoma (HCC) as it provides a modest but significant increase in survival rate in patients with advanced HCC [1]. Initially developed as a Raf-1 kinase inhibitor, sorafenib also targets other Raf kinase isoforms (wild-type B-Raf and oncogenic B-Raf V600) and receptor tyrosine kinases such as vascular endothelial growth factor receptors (VEGFR-2 and -3), platelet-derived growth factor-β (PDGFR-β), Flt-3, and c-Kit. More recently, the BCR/ABL kinase has been also identified as a sorafenib target [2].
No takes yet. Share an insight, caveat, or question.
Rosmorduc et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: